Moleculin Competitors

Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Moleculin Biotech's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Moleculin Biotech in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
0.081.505.45
Details
Intrinsic
Valuation
LowReal ValueHigh
1.355.869.81
Details
Naive
Forecast
LowNext ValueHigh
0.0293161.475.41
Details
3 Analysts
Consensus
LowTarget PriceHigh
10.0019.0029.00
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Moleculin Biotech. Your research has to be compared to or analyzed against Moleculin Biotech's peers to derive any actionable benefits. When done correctly, Moleculin Biotech's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Moleculin Biotech.

Moleculin Biotech Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Moleculin Biotech and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Moleculin and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Moleculin Biotech does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Moleculin Biotech Competition Risk-Adjusted Indicators

Nowadays, there is a big difference between Moleculin Biotech stock performing well and Moleculin Biotech company doing well compared to the competition. There are way too many exceptions to the normal that investors can tell for sure what's good or bad unless they analyze Moleculin Biotech's multiple risk-adjusted performance indicators. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean
Deviation
Jensen
Alpha
Sortino
Ratio
Treynor
Ratio
Semi
Deviation
Information
Ratio
Expected
Shortfall
Potential
Upside
Value
At Risk
Maximum
Drawdown
TWTR 2.84  0.15  0.06  0.10  3.55  0.05 (2.99)  5.66 (5.40)  36.79 
MSFT 1.94  0.04  0.00 (0.15)  0.00 (0.0155)  0.00  2.97 (4.24)  9.36 
UBER 3.38 (0.29)  0.00 (0.33)  0.00 (0.11)  0.00  6.55 (7.19)  18.56 
F 2.44 (0.21)  0.00 (0.31)  0.00 (0.10)  0.00  3.89 (5.54)  16.83 
T 1.29  0.37  0.26  0.39  1.38  0.24 (1.47)  2.99 (2.47)  12.17 
A 1.99  0.03  0.00 (0.15)  0.00 (0.0062)  0.00  3.19 (3.50)  9.77 
CRM 2.65  0.03  0.00 (0.16)  0.00 (0.0291)  0.00  6.33 (5.28)  16.84 
JPM 1.43 (0.11)  0.00 (0.29)  0.00 (0.06)  0.00  2.98 (3.00)  10.78 
MRK 1.05  0.29  0.34  0.42  0.95  0.28 (1.23)  2.16 (1.65)  7.61 
XOM 1.94  0.24  0.09  0.10  2.91  0.11 (1.70)  3.03 (3.96)  11.86 

Moleculin Biotech Competitive Analysis

The better you understand Moleculin Biotech competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Moleculin Biotech's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Moleculin Biotech's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart

Moleculin Biotech Competition Performance Charts

Complement your Moleculin Biotech position

In addition to having Moleculin Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Utilities Thematic Idea Now

Utilities
Utilities Theme
Highly leveraged corporations that deliver utilities such as power, water or gas to public or business. The Utilities theme has 30 constituents.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Utilities Theme or any other thematic opportunities.
View All  Next Launch Utilities
Additionally, see Moleculin Biotech Correlation with its peers. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
MBRX
 Stock
  

USD 1.49  0.01  0.67%   

Analyzing Moleculin Biotech competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Moleculin Biotech to its intrinsic valuation because they are able to contrast its competitors on a relative basis.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Moleculin Biotech competition on your existing holdings. Additionally, see Moleculin Biotech Correlation with its peers.
  
Refresh
Return on Invested Capital is likely to rise to 12.52 in 2022, whereas Return on Average Assets are likely to drop (0.19)  in 2022. Moleculin Biotech Total Assets are fairly stable at the moment as compared to the past year. Moleculin Biotech reported Total Assets of 84.09 Million in 2021. Current Assets is likely to rise to about 78.2 M in 2022, whereas Goodwill and Intangible Assets are likely to drop slightly above 10 M in 2022.